文献速递药物不良反应与药物警戒肝肾功能剂量调整特殊人群用药

别嘌醇致严重皮肤不良反应的非遗传风险因素系统综述

Non-genetic Risk Factors for Allopurinol-Induced Severe Cutaneous Adverse Reaction (SCAR): A Systematic Review.
PubMed 文献 · Drug Saf · 2026-09-15

该系统综述纳入26项观察性研究,评估成人别嘌醇所致严重皮肤不良反应(SCAR)的非遗传风险因素。女性(OR 2.06,95%CI 1.25-3.38)、慢性肾病(OR 3.78,95%CI 1.99-7.17)及较高别嘌醇剂量与SCAR风险增加相关,年龄和合并使用利尿剂在主分析中无显著关联。

要点

  • 女性别嘌醇相关SCAR风险约为男性的2倍。
  • SCAR病例的别嘌醇平均剂量比耐受对照高19.61 mg。

核心结论

  • 慢性肾病、女性性别和较高别嘌醇剂量是别嘌醇诱导SCAR的显著非遗传风险因素。
  • 上述发现支持在未来风险分层策略中,将非遗传因素与药物基因组学筛查一并考虑。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Scopus、Cochrane Library和Web of Science至2026年6月29日。
  • 纳入26项观察性研究,受试者为年龄≥18岁的成人。
  • 采用随机效应模型计算合并比值比(OR)及95%置信区间(CI),用I²评估异质性。

主要发现

  • 女性与别嘌醇诱导SCAR风险增加相关(20项研究;3340例SCAR病例,562647例对照;OR 2.06,95%CI 1.25-3.38)。
  • 慢性肾病与SCAR显著相关(16项研究;1625例SCAR病例,553804例对照;OR 3.78,95%CI 1.99-7.17)。
  • SCAR病例的别嘌醇剂量高于耐受对照(5项研究;177例SCAR病例,1368例对照;平均差19.61 mg,95%CI 2.97-36.24)。
  • 主荟萃分析中未观察到年龄或合并使用利尿剂与SCAR的显著关联。
  • 排除非亚洲研究和零事件研究后,合并使用利尿剂与SCAR变为显著相关。

关键数值与推荐

  • SCAR定义为Stevens-Johnson综合征、中毒性表皮坏死松解症、急性泛发性发疹性脓疱病或伴嗜酸性粒细胞增多和系统症状的药物反应/超敏综合征。

临床怎么用

  • 对慢性肾病患者和女性患者处方别嘌醇时,应更重视SCAR风险预警与患者教育。
  • 在条件允许时,考虑将非遗传风险因素与HLA-B*58:01筛查结合用于风险分层。

局限性

  • 研究间存在显著异质性。
  • 可能存在发表偏倚,限制证据确定性。
  • 需要以非遗传预测因素为主要结局的精心设计研究来构建稳健的综合风险预测模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allopurinol-induced severe cutaneous adverse reactions (SCARs) are rare but potentially life threatening, particularly in Asian populations. While the genetic marker HLA-B*58:01 is a well-established risk factor, non-genetic factors may also contribute. This systematic review synthesizes evidence on associations between non-genetic risk factors and allopurinol-induced SCAR. METHODS: We searched MEDLINE, Scopus, Cochrane Library and Web of Science from inception to 29 June 2026 for observational studies examining non-genetic risk factors for SCAR, defined as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Acute Generalised Exanthematous Pustulosis, or Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Adults aged ≥ 18 years were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model; heterogeneity was assessed with I2. Mean differences were calculated for continuous variables. NIH Study Quality Assessment Tool was used for quality assessment of the studies. RESULTS: Twenty-six studies were included. Female sex (20 studies; 3340 SCAR cases, 562,647 controls) was associated with an increased risk of allopurinol-induced SCAR (OR 2.06; 95% confidence interval (CI) 1.25-3.38). Chronic kidney disease (16 studies; 1625 SCAR cases, 553,804 controls) was also significantly associated with SCAR (OR 3.78; 95% CI 1.99-7.17). Five studies (177 SCAR cases, 1368 controls) reported higher allopurinol doses among SCAR cases than tolerant controls (mean difference 19.61 mg; 95% CI 2.97-36.24). No significant associations were observed for age or concomitant diuretic use in the primary meta-analyses. Substantial heterogeneity was observed across studies. Sensitivity analyses demonstrated consistent findings for most factors, although concomitant diuretic use became significantly associated with SCAR after exclusion of non-Asian and zero-event studies. CONCLUSION: CKD, female sex, and higher allopurinol dose were identified as significant non-genetic risk factors for allopurinol-induced SCAR. These findings support consideration of non-genetic factors alongside pharmacogenomic screening in future risk-stratification strategies. However, substantial heterogeneity and potential publication bias limit the certainty of the available evidence. Well-designed studies evaluating non-genetic predictors as primary outcomes are needed to develop robust integrated risk prediction models for clinical decision making.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Ng WL, Oka P, Chong K, et al. Non-genetic Risk Factors for Allopurinol-Induced Severe Cutaneous Adverse Reaction (SCAR): A Systematic Review. Drug Saf. 2026. PMID: 42742931. doi:10.1007/s40264-026-01729-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。